A designer drug for amyloid polyneuropathy

Neurology

Volumn 79, Issue 8, 2012, Pages 730-731

  Chalk, Colin ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TAFAMIDIS;

DRUG EFFICACY; EDITORIAL; FAMILIAL AMYLOID POLYNEUROPATHY; HUMAN; NEUROLOGIC EXAMINATION; NEUROPATHY IMPAIRMENT SCORE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; TREATMENT RESPONSE;

EID: 84866065795     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182662041     Document Type: Editorial

References (5)

1. Pareyson D, Reilly M, Schenone A, et al. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMTTRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 2011;10:320-328.
2. Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012;79:785-792.
3. Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011;10:1086-1097.
4. Yamashita T, Ando Y, Okamoto S, et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 2012;78:637-643.
5. Hammarström P, Wiseman RL, Powers ET, Kelly JW. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003;299:713-716.